pyrazines has been researched along with Granulocytic Leukemia, Chronic in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (27.59) | 29.6817 |
| 2010's | 19 (65.52) | 24.3611 |
| 2020's | 2 (6.90) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, H; Kim, IS | 1 |
| Fan, Z; Lai, Q; Li, S; Liang, A; Luo, H; Wang, F; Wang, G; Wang, J; Xu, J; Xu, Y; Zhang, W; Zhou, J | 1 |
| Breccia, M; Colafigli, G; Massaro, F; Molica, M | 1 |
| Do, YR; Jo, DJ; Jung, SY; Kim, DW; Kim, SH; Kwak, JY; Lee, JI; Lee, S; Noh, H; Oh, SJ; Park, HL; Shin, JS; Zang, DY | 1 |
| Jue, MS; Park, E | 1 |
| Cheon, S; Cho, D; Cho, DJ; Hur, DY; Kim, DY; Kim, KE; Park, HJ; Park, JM; Park, S | 1 |
| Abdulkadyrov, KM; Bessmel'tsev, SS; Martynkevich, IS; Romanenko, NA; Rugal', VI; Udal'eva, VIu; Zenina, MN | 1 |
| Ma, LM; Zhao, J | 1 |
| Wei, W; Wu, C; Wu, Y; Xu, W; Yan, H; Ye, C; Yu, Q | 1 |
| Chen, Z; Hu, S; Rich, A; Tang, G; Wang, W | 1 |
| Katzel, JA; Lee-Ma, A; Vesole, DH | 1 |
| Jung, YS; Kim, DW; Kim, M; Lee, JH; Park, HJ | 1 |
| Cho, DJ; Kim, DW; Kim, SH; Lee, JI; Noh, H; Oh, SJ; Park, HL; Park, MS; Zang, DY | 1 |
| Kim, DW; Kim, M; Lee, JH; Park, HJ; Yoon, YH | 1 |
| Adams, S; Barrett, AJ; Berg, M; Childs, R; Eniafe, R; Goldman, JM; Hensel, N; Keyvanfar, K; Lundqvist, A; Savani, BN; Sloand, EM; Yong, AS | 1 |
| Kagechika, H; Kurosu, T; Miura, O; Ohki, M; Wu, N | 1 |
| Allan, EK; Bhatia, R; Chu, S; Crawford, L; Heaney, NB; Holyoake, TL; Irvine, AE; Jorgensen, HG; Kazmi, SM; Pellicano, F; Zhang, B | 1 |
| Agirre, X; Albero, MP; Andreu, EJ; Franch, L; Ivorra, C; Pérez-Roger, I; Poch, E; Prosper, F; Vaquer, JM; Villanueva, JJ | 1 |
| Li, QF; Wang, H; Wang, LS; Wu, CT; Xiao, FJ; Yan, J; Yang, YF; Zhang, K | 1 |
| Blaskovich, MA; Burton, M; Cubitt, C; Duong, VH; Lancet, JE; Sebti, S; Stuart, RK; Sullivan, DM; Winton, EF; Wright, JJ; Zhang, S | 1 |
| Barbetti, V; Dello Sbarba, P; Giuntoli, S; Rovida, E; Tanturli, M | 1 |
| Borthakur, G; Cortes, J; Faderl, S; Ferrajoli, A; Kantarjian, H; McConkey, D; O'Brien, S; Santos, FP; Wright, J | 1 |
| Cao, R; He, H; Huang, KK; Jiang, XJ; Liao, LB; Lin, R; Meng, FY; Wang, Q; Wu, FQ; Xu, D; Yang, M; Yi, ZS; Yin, CX; Zheng, ZX; Zhou, HS | 1 |
| Conrad, D; Dent, P; Grant, S; Rahmani, M; Subler, M; Yu, C | 1 |
| Dai, Y; Dent, P; Grant, S; Pei, XY; Rahmani, M | 1 |
| Hatake, K; Mishima, Y; Terui, Y | 1 |
| Andreeff, M; Ashihara, E; Kamitsuji, Y; Kawata, E; Kimura, S; Kuroda, J; Maekawa, T; O'Reilly, LA; Strasser, A; Tabe, Y; Takeuchi, M; Tanaka, R; Taniwaki, M; Yokota, A | 1 |
| Fu, YB; Li, CY; Li, L; Meng, FY; Song, LL; Sun, QX; Yi, ZS | 1 |
| Irvine, AE; McCloskey, SM; McMullin, MF; Walker, B | 1 |
5 review(s) available for pyrazines and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Novel tyrosine-kinase inhibitors for the treatment of chronic myeloid leukemia: safety and efficacy.
Topics: Amino Acid Substitution; Benzamides; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation, Missense; Protein Kinase Inhibitors; Pyrazines; Translocation, Genetic | 2018 |
Radotinib-induced eruptive melanocytic nevi in patient with chronic myeloid leukemia: a case report and literature review.
Topics: Aged; Benzamides; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasms, Second Primary; Nevus, Pigmented; Pyrazines; Skin Neoplasms | 2019 |
Eruptive Melanocytic Naevi Caused by Radotinib Therapy in Patients with Chronic Myeloid Leukaemia: 10 cases and a literature Review.
Topics: Adult; Aged; Benzamides; Drug Eruptions; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nevus, Pigmented; Pyrazines | 2017 |
[Proteasome inhibitors].
Topics: Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cysteine Endopeptidases; Humans; Kidney Neoplasms; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multienzyme Complexes; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines | 2004 |
The therapeutic potential of the proteasome in leukaemia.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Clinical Trials as Topic; Gene Expression Regulation, Leukemic; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medical Oncology; Models, Biological; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Recurrence | 2008 |
3 trial(s) available for pyrazines and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Determination of a radotinib dosage regimen based on dose-response relationships for the treatment of newly diagnosed patients with chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Dose-Response Relationship, Drug; Drug Dosage Calculations; Female; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Weight; Pyrazines; Treatment Outcome; Young Adult | 2018 |
Optimization of radotinib doses for the treatment of Asian patients with chronic myelogenous leukemia based on dose-response relationship analyses.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Benzamides; Body Surface Area; Body Weight; Dose-Response Relationship, Drug; Drug Dosage Calculations; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Protein Kinase Inhibitors; Pyrazines; Treatment Outcome; Young Adult | 2016 |
A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chymotrypsin; Farnesyltranstransferase; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Male; Maximum Tolerated Dose; Middle Aged; NF-kappa B; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Inhibitors; Pyrazines; Quinolones | 2011 |
21 other study(ies) available for pyrazines and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Emergence of
Topics: Aniline Compounds; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Pyrazines | 2023 |
Checkpoint kinase‑1 inhibition and etoposide exhibit a strong synergistic anticancer effect on chronic myeloid leukemia cell line K562 by impairing homologous recombination DNA damage repair.
Topics: 4-Aminopyridine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Checkpoint Kinase 1; Comet Assay; DNA Damage; DNA Repair; Drug Synergism; Etoposide; Homologous Recombination; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrazines; Topoisomerase II Inhibitors | 2020 |
Novel Application of Radotinib for the Treatment of Solid Tumors via Natural Killer Cell Activation.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cytotoxicity, Immunologic; fas Receptor; Fusion Proteins, bcr-abl; Humans; Immunity, Innate; Immunotherapy; K562 Cells; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Activation; Neoplasms; Pyrazines; RNA, Small Interfering | 2018 |
[The combination of chronic myeloid leukemia and multiple myeloma in one patient].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Imatinib Mesylate; Induction Chemotherapy; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Piperazines; Polyneuropathies; Pyrazines; Pyrimidines; Recurrence; Watchful Waiting | 2013 |
[Effect of bortezomib on reverse multidrug resistance and XIAP expression in imatinib-resistant primary cells of chronic myeloid leukemia in blastic crisis].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Proteasome Inhibitors; Pyrazines; Pyrimidines; Tumor Cells, Cultured; X-Linked Inhibitor of Apoptosis Protein; Young Adult | 2013 |
Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr/Abl‑dependent mechanisms.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Poly(ADP-ribose) Polymerases; Pyrazines; Pyrimidines; Reactive Oxygen Species; RNA, Messenger | 2014 |
Myeloid sarcoma as the initial presentation of chronic myelogenous leukemia, medullary chronic phase in era of tyrosine kinase inhibitors: A report of 11 cases.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Protein Kinase Inhibitors; Pyrazines; Sarcoma, Myeloid; Survival Analysis | 2015 |
Safety of a second-generation tyrosine kinase inhibitor and novel targeted therapy for the treatment of a patient with chronic myeloid leukemia and multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multiple Myeloma; Protein-Tyrosine Kinases; Pyrazines; Pyrimidines | 2015 |
Acneiform eruptions caused by various second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia.
Topics: Acneiform Eruptions; Adult; Benzamides; Dasatinib; Facial Dermatoses; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Pyrimidines; Young Adult | 2016 |
Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib.
Topics: Adolescent; Adult; Antigens, CD34; Boronic Acids; Bortezomib; Cell Separation; Cells, Cultured; Female; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Genotype; Humans; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Monomeric GTP-Binding Proteins; Pyrazines; Receptors, Death Domain; Up-Regulation | 2009 |
Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Topics: Acetophenones; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Benzenesulfonates; Benzopyrans; Biphenyl Compounds; Boronic Acids; Bortezomib; Caspases; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interleukin-3; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitochondria; Mutation; Niacinamide; Nitrophenols; Phenylurea Compounds; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Pyridines; Pyrimidines; Sorafenib; Sulfonamides | 2009 |
Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells.
Topics: Animals; Antigens, CD34; Apoptosis; Boronic Acids; Bortezomib; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Dasatinib; Drug Synergism; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, SCID; Mutant Proteins; Proteasome Inhibitors; Pyrazines; Pyrimidines; Thiazoles; Time Factors; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2010 |
Bortezomib decreases Rb phosphorylation and induces caspase-dependent apoptosis in Imatinib-sensitive and -resistant Bcr-Abl1-expressing cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Caspases; Cell Growth Processes; Cell Line, Tumor; Electrophoretic Mobility Shift Assay; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; NF-kappa B; Phosphorylation; Piperazines; Pyrazines; Pyrimidines; Retinoblastoma Protein | 2010 |
Bortezomib and sphingosine kinase inhibitor interact synergistically to induces apoptosis in BCR/ABl+ cells sensitive and resistant to STI571 through down-regulation Mcl-1.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloid Cell Leukemia Sequence 1 Protein; Phosphotransferases (Alcohol Group Acceptor); Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrimidines | 2011 |
Hypoxia selects bortezomib-resistant stem cells of chronic myeloid leukemia.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Hypoxia; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Pyrazines | 2011 |
Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase.
Topics: Aged; Apoptosis; Basophils; Benzamides; Boronic Acids; Bortezomib; Drug Resistance; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pilot Projects; Piperazines; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyrimidines | 2011 |
Imatinib and bortezomib induce the expression and distribution of anaphase-promoting complex adaptor protein Cdh1 in blast crisis of chronic myeloid leukemia.
Topics: Adult; Antigens, CD; Antineoplastic Agents; Benzamides; Blast Crisis; Boronic Acids; Bortezomib; Cadherins; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Nucleus; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Knockdown Techniques; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrazines; Pyrimidines; RNA Interference; S-Phase Kinase-Associated Proteins; Young Adult | 2012 |
The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Butyrates; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protease Inhibitors; Pyrazines; Pyrimidines; Reactive Oxygen Species; Signal Transduction; Tumor Cells, Cultured; Vorinostat | 2003 |
Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Boronic Acids; Bortezomib; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Flavonoids; Fusion Proteins, bcr-abl; Humans; I-kappa B Proteins; Imatinib Mesylate; In Vitro Techniques; JNK Mitogen-Activated Protein Kinases; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Milk Proteins; Mitochondria; Mitogen-Activated Protein Kinases; NF-kappa B; Nuclear Proteins; Phosphoprotein Phosphatases; Phosphorylation; Piperazines; Piperidines; Pyrazines; Pyrimidines; RNA Polymerase II; src-Family Kinases; STAT3 Transcription Factor; STAT5 Transcription Factor; Trans-Activators | 2004 |
Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Benzoquinones; Biphenyl Compounds; Boronic Acids; Bortezomib; Cell Line, Transformed; Cell Line, Tumor; Humans; Imatinib Mesylate; Lactams, Macrocyclic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-bcr; Pyrazines; Pyrimidines; Sulfonamides | 2007 |
[STI571 enhances the effect of arsenic trioxide and Velcade on bcr/abl+-CD34+ cell proliferation and apoptosis].
Topics: Adult; Aged; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Boronic Acids; Bortezomib; Cell Proliferation; Drug Synergism; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Oxides; Piperazines; Pyrazines; Pyrimidines; Tumor Cells, Cultured | 2007 |